Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

The executive order aims to lower prescription prices, but targets the mechanism for negotiating small molecule drug costs.

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...